Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a ...

Inflammation is linked to the development of psychiatric illness. Recently, data has emerged on the usefulness of treating ...

SNRIs are often preferred for treating more severe cases of depression. Common examples include duloxetine, desvenlafaxine ...

Supernus Pharmaceuticals has said its candidate SPN-820, demonstrated a “rapid and substantial” effect in a Phase IIa trial ...

Boston-based Seaport said the money would support a pipeline of improved neuropsychiatric drug candidates led by SPT-300, an ...

On October 11, the recall was classified as a class II recall by the FDA—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health ...

There was nothing else to do, so I was like, 'oh, I'll just go and do it, why not?'' It was once considered a 'dirty' drug ...

The Boston-based startup is developing what executives hope will be more effective treatments for depression, anxiety, and ...

Scientists are learning more about how psychedelic mushrooms may alter the brain, potentially leading to long-lasting ...

New, non-hallucinogenic versions of psychedelics are blurring the boundaries of the drug trip.